Supplementary Figure 2: Effect of sunitinib and sorafenib on metastatic Lewis Lung carcinoma.

LLC cells were injected in the tibial muscle of C57/BL6 mice, which received either vehicle, sunitinib or sorafenib (30 and 40 mg/kg, ↑, 10/group) for twelve days starting from day 7 when tumors were palpable (60-80 mm³). (A) Antitumor activity of sunitinib and sorafenib (mean tumor volume ± s.e.m, ** p<0.01, ***p<0.001). Number of metastatic nodules (B) at the end of treatment (day 19, interim): mean tumor volume ~1900, 1500, 1000 mm³ for vehicle, sunitinib and sorafenib respectively, and (C) at scheduled death (primary tumor volume 2000 mm³, terminal). (*p<0.05, *** p<0.001 vs. vehicle). Lung metastases were plotted as total number (left) or as number of metastases divided per diameter size (■ diameter >3mm ■ 2mm < diameter < 3mm ■ 1mm < diameter < 2mm ■ diameter <1mm).